INFU vs. KIDS, AXGN, NPCE, OM, TMCI, SMLR, CLPT, NNOX, SNWV, and NYXH
Should you be buying InfuSystem stock or one of its competitors? The main competitors of InfuSystem include OrthoPediatrics (KIDS), AxoGen (AXGN), NeuroPace (NPCE), Outset Medical (OM), Treace Medical Concepts (TMCI), Semler Scientific (SMLR), ClearPoint Neuro (CLPT), Nano-X Imaging (NNOX), SANUWAVE Health (SNWV), and Nyxoah (NYXH). These companies are all part of the "medical equipment" industry.
InfuSystem vs. Its Competitors
InfuSystem (NYSE:INFU) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and community ranking.
In the previous week, InfuSystem had 2 more articles in the media than OrthoPediatrics. MarketBeat recorded 2 mentions for InfuSystem and 0 mentions for OrthoPediatrics. InfuSystem's average media sentiment score of 1.75 beat OrthoPediatrics' score of 0.00 indicating that InfuSystem is being referred to more favorably in the media.
InfuSystem has a beta of 1.81, indicating that its share price is 81% more volatile than the S&P 500. Comparatively, OrthoPediatrics has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500.
71.1% of InfuSystem shares are owned by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are owned by institutional investors. 11.4% of InfuSystem shares are owned by insiders. Comparatively, 32.7% of OrthoPediatrics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
InfuSystem currently has a consensus target price of $13.00, suggesting a potential upside of 110.02%. OrthoPediatrics has a consensus target price of $35.83, suggesting a potential upside of 77.83%. Given InfuSystem's stronger consensus rating and higher probable upside, equities research analysts plainly believe InfuSystem is more favorable than OrthoPediatrics.
InfuSystem has higher earnings, but lower revenue than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.
InfuSystem has a net margin of 1.12% compared to OrthoPediatrics' net margin of -19.15%. InfuSystem's return on equity of 2.78% beat OrthoPediatrics' return on equity.
OrthoPediatrics received 306 more outperform votes than InfuSystem when rated by MarketBeat users. However, 100.00% of users gave InfuSystem an outperform vote while only 64.43% of users gave OrthoPediatrics an outperform vote.
Summary
InfuSystem beats OrthoPediatrics on 14 of the 19 factors compared between the two stocks.
Get InfuSystem News Delivered to You Automatically
Sign up to receive the latest news and ratings for INFU and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding INFU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
InfuSystem Competitors List
Related Companies and Tools
This page (NYSE:INFU) was last updated on 6/19/2025 by MarketBeat.com Staff
Buy INFU Stock Free INFU Stock Alerts